全球靜脈注射鐵劑市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計靜脈注射鐵劑市場將從 2025 年的 26 億美元成長到 2034 年的 48.3 億美元，2026 年至 2034 年的複合年成長率為 7.12%。

隨著慢性腎臟病、腫瘤和發炎性腸道疾病等慢性疾病中缺鐵性貧血的診斷率不斷上升，靜脈鐵劑市場正迅速成長。由於靜脈鐵劑比口服鐵劑更快補充鐵蘊藏量，因此在需要快速改善病情或口服治療無效時，靜脈注射鐵劑是臨床上的首選。醫院靜脈輸液服務的擴展以及針對特定患者群體推薦使用靜脈鐵劑的指南的更新，都促進了靜脈鐵劑使用量的成長。

關鍵促進因素包括慢性病盛行率上升、貧血篩檢通訊協定改善以及臨床醫生對靜脈鐵劑療效和安全性的認知不斷提高。新型製劑可實現高劑量單次給藥並縮短輸注時間，提高了給藥的可行性和患者的便利性，從而加速了住院和門診輸液中心對靜脈鐵劑的推廣應用。成本趨勢和支付方政策仍然是重要的影響因素；有利的報銷方案和明確的指南建議能夠促進靜脈鐵劑的推廣應用，而有限的保險覆蓋範圍則可能減緩其普及。

展望未來，由於人口結構變化導致合格的患者群體增加，以及研發公司推出耐受性更好、給藥更便捷的製劑，預計市場將進一步擴張。生物相似藥的上市和價格競爭壓力將有助於提高藥物可及性，而以降低住院率和輸血率為評估指標的價值醫療模式，如果靜脈鐵劑療法的成本效益得到證實，則將更受青睞。製藥公司與輸液服務提供者之間的策略合作可以進一步簡化給藥流程和後續的患者追蹤。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球靜脈注射鐵劑產品市場：依藥物類型分類

• 市場分析、洞察與預測
• 聚葡萄糖鐵
• 蔗糖鐵
• 羧基Carboxymaltose鐵
• 其他藥物類型

第5章：全球靜脈注射鐵劑產品市場：依應用分類

• 市場分析、洞察與預測
• 慢性腎臟病
• 發炎性腸道疾病
• 癌症
• 其他用途

第6章：全球靜脈注射鐵劑產品市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球靜脈注射鐵劑產品市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • AbbVie Inc
  • AdvaCare Pharma
  • Akebia Therapeutics Inc
  • AMAG Pharmaceuticals Inc
  • Bayer AG
  • Covis Pharma GmbH
  • CSL Limited
  • Daiichi Sankyo Company Ltd
  • F. Hoffmann-La Roche Ltd
  • Fresenius SE & Co. KGaA
  • Novartis AG
  • Pharmacosmos A/S

The Intravenous Iron Drugs Market size is expected to reach USD 4.83 Billion in 2034 from USD 2.60 Billion (2025) growing at a CAGR of 7.12% during 2026-2034.

The intravenous iron drugs market has grown rapidly in response to higher diagnosis rates of iron-deficiency anemia across chronic diseases such as chronic kidney disease, oncology, and inflammatory bowel disease. IV iron formulations allow faster repletion of iron stores than oral supplements, making them clinically preferred in settings where rapid correction is needed or oral therapy fails. Expansion of hospital-based infusion services and evolving guideline endorsements for IV iron in specific patient populations have contributed to increased utilization.

Drivers include rising chronic disease prevalence, better anemia screening protocols, and broader clinician acceptance of IV iron's efficacy and safety. Newer formulations that allow higher single-dose administration and reduced infusion times improve logistical feasibility and patient convenience, encouraging adoption in both inpatient and outpatient infusion centers. Cost dynamics and payer policies remain important variables-favorable reimbursement and clear guideline recommendations accelerate uptake, whereas restrictive coverage can slow access.

Looking ahead, the market is set to expand as demographic shifts increase the pool of eligible patients and as developers introduce formulations with improved tolerability and dosing convenience. Biosimilar entrants and competitive pricing pressures could broaden access, while value-based care models that reward reduced hospitalization and transfusion rates will favor IV iron therapies when cost-effectiveness is demonstrated. Strategic alliances between drug manufacturers and infusion providers may further streamline delivery and patient follow-through.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Iron Dextran
• Iron Sucrose
• Ferric Carboxymaltose
• Other Drug Types

By Application

• Chronic Kidney Disease
• Inflammatory Bowel Disease
• Cancer
• Other Applications

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

COMPANIES PROFILED

• AbbVie Inc, AdvaCare Pharma, Akebia Therapeutics Inc, AMAG Pharmaceuticals Inc, Bayer AG, Covis Pharma GmbH, CSL Limited, Daiichi Sankyo Company Ltd, F HoffmannLa Roche Ltd, Fresenius SE Co KGaA, Novartis AG, Pharmacosmos AS
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL INTRAVENOUS IRON DRUGS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Iron Dextran Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Iron Sucrose Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Ferric Carboxymaltose Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Other Drug Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL INTRAVENOUS IRON DRUGS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Chronic Kidney Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Inflammatory Bowel Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL INTRAVENOUS IRON DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL INTRAVENOUS IRON DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Type
  • 7.2.2 By Application
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Type
  • 7.3.2 By Application
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Type
  • 7.4.2 By Application
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Type
  • 7.5.2 By Application
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Type
  • 7.6.2 By Application
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL INTRAVENOUS IRON DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 AbbVie Inc
  • 9.2.2 AdvaCare Pharma
  • 9.2.3 Akebia Therapeutics Inc
  • 9.2.4 AMAG Pharmaceuticals Inc
  • 9.2.5 Bayer AG
  • 9.2.6 Covis Pharma GmbH
  • 9.2.7 CSL Limited
  • 9.2.8 Daiichi Sankyo Company Ltd
  • 9.2.9 F. Hoffmann-La Roche Ltd
  • 9.2.10 Fresenius SE & Co. KGaA
  • 9.2.11 Novartis AG
  • 9.2.12 Pharmacosmos A/S